Wellington Management Group LLP Has $106.02 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wellington Management Group LLP cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 66.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 148,829 shares of the biopharmaceutical company's stock after selling 291,780 shares during the quarter. Wellington Management Group LLP owned 0.14% of Regeneron Pharmaceuticals worth $106,015,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in REGN. Clearbridge Investments LLC lifted its position in shares of Regeneron Pharmaceuticals by 0.7% in the 4th quarter. Clearbridge Investments LLC now owns 3,978 shares of the biopharmaceutical company's stock worth $2,834,000 after buying an additional 26 shares during the last quarter. RWA Wealth Partners LLC raised its stake in Regeneron Pharmaceuticals by 4,518.0% during the fourth quarter. RWA Wealth Partners LLC now owns 18,426 shares of the biopharmaceutical company's stock worth $13,125,000 after acquiring an additional 18,027 shares during the period. Allianz SE bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $96,000. Allstate Corp acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $2,276,000. Finally, Brown Brothers Harriman & Co. grew its holdings in shares of Regeneron Pharmaceuticals by 9.3% during the fourth quarter. Brown Brothers Harriman & Co. now owns 527 shares of the biopharmaceutical company's stock valued at $375,000 after purchasing an additional 45 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $2.78 during trading hours on Tuesday, hitting $570.00. 240,201 shares of the company were exchanged, compared to its average volume of 689,748. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market capitalization of $62.32 billion, a PE ratio of 14.89, a PEG ratio of 2.34 and a beta of 0.44. The firm has a fifty day simple moving average of $674.46 and a 200-day simple moving average of $772.53. Regeneron Pharmaceuticals, Inc. has a one year low of $557.83 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $11.86 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Analyst Ratings Changes

A number of research firms recently issued reports on REGN. UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a report on Monday, March 31st. Bank of America restated an "underperform" rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.